Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.6.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2026. Verfasst von Yunyun Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China. Hauptthemen laut MEDLINE: Uveomeningoencephalitic Syndrome, Adalimumab, Macrophages, Th1 Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
- Postdoctoral Mobile Station of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
- Department of Ophthalmology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
- Department of Emergency, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
- Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China.
- Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Zitieren
APA
Zhu, Y., Yu, Q., Ma, Y., Huang, L., Ding, J., Gao, X., Ma, L., Zhang, D., Zhang, B., Wang, S., Chu, W. K., Su, G., & Yang, P. (2026). Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.6.4
Vancouver
Zhu Y, Yu Q, Ma Y, Huang L, Ding J, Gao X, et al. Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.6.4
BibTeX
@article{Zhu2026,
author = {Zhu, Yunyun and Yu, Qiuyue and Ma, Yangyang and Huang, Li and Ding, Jianguang and Gao, Xiuhua and Ma, Lili and Zhang, Dike and Zhang, Bin and Wang, Sen and Chu, Wai Kit and Su, Guannan and Yang, Peizeng},
title = {Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt–Koyanagi–Harada Syndrome},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.6.4}
}
EUVIMED